1. Adelaide Research & Scholarship

Search


Current filters:



Start a new search
Add filters:

Use filters to refine the search results.

 | 
Results 1-8 of 8 (Search time: 0.002 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2015Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancerPrice, T.; Bruhn, M.; Lee, C.; Hardingham, J.; Townsend, A.; Mann, K.; Simes, J.; Weickhardt, A.; Wrin, J.; Wilson, K.; Gebski, V.; Van Hazel, G.; Robinson, B.; Cunningham, D.; Tebbutt, N.
2013Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapyPadman, S.; Padbury, R.; Beeke, C.; Karapetis, C.; Bishnoi, S.; Townsend, A.; Maddern, G.; Price, T.
2012Impact of age on choice of chemotherapy and outcome in advanced colorectal cancerKhattak, M.; Townsend, A.; Beeke, C.; Karapetis, C.; Luke, C.; Padbury, R.; Maddern, G.; Roder, D.; Price, T.
2010Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancerPeeters, M.; Price, T.; Cervantes, A.; Sobrero, A.; Ducreux, M.; Hotko, Y.; Andre, T.; Chan, E.; Lordick, F.; Punt, C.; Strickland, A.; Wilson, G.; Ciuleanu, T.; Roman, L.; Van Cutsem, E.; Tzekova, V.; Collins, S.; Oliner, K.; Rong, A.; Gansert, J.
2010Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian gastrointestinal trials group randomized phase III MAX studyTebbutt, N.; Wilson, K.; Gebski, V.; Cummins, M.; Zannino, D.; van Hazel, G.; Robinson, B.; Broad, A.; Ganju, V.; Ackland, S.; Forgeson, G.; Cunningham, D.; Saunders, M.; Stockler, M.; Chua, Y.; Zalcberg, J.; Simes, R.; Price, T.
2012Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: Preclinical evaluation and results of the Phase II DUX Study in chemotherapy-refractory, advanced colorectal cancerWeickhardt, A.; Price, T.; Chong, G.; Gebski, V.; Pavlakis, N.; Johns, T.; Azad, A.; Skrinos, E.; Fluck, K.; Dobrovic, A.; Salemi, R.; Scott, A.; Mariadason, J.; Tebbutt, N.
2011Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancerHaller, D.; Tabernero, J.; Maroun, J.; de Braud, F.; Price, T.; Van Cutsem, E.; Hill, M.; Gilberg, F.; Rittweger, K.; Schmoll, H.
2015Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI zlone as second-line treatment for metastatic colorectal cancerPeeters, M.; Oliner, K.; Price, T.; Cervantes, A.; Sobrero, A.; Ducreux, M.; Hotko, Y.; André, T.; Chan, E.; Lordick, F.; Punt, C.; Strickland, A.; Wilson, G.; Ciuleanu, T.; Roman, L.; Van Cutsem, E.; He, P.; Yu, H.; Koukakis, R.; Terwey, J.; et al.

Discover